Clinical Trial Update: Lactobacillus Brevis CD2 Preventing Oral Mucositis [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on Lactobacillus brevis CD2 for preventing oral mucositis, studied in Phase 2 and Phase 3. Current status of the trial is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Mucositis

Drugs mentioned

• Lactobacillus brevis CD2 (Lactobacillus brevis CD2)

Snippet

Sponsor: Catholic University of the Sacred Heart | Conditions: Mucositis | Phase 2, Phase 3 | Status: UNKNOWN